

April 16, 2025

<b>BSE Limited</b> P J Towers, Dalal Street, <u>Mumbai-400001</u>	<b>Code: 532321</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u>	<b>Code: Zyduslife</b>
--	---------------------	--	------------------------

Sub.: Clarification/Confirmation on news item appearing in "[www.cnbcvtv18.com](http://www.cnbcvtv18.com)"

Ref.: Emails dated April 16, 2025, from National Stock Exchange of India Limited and BSE Limited

Dear Sir / Madam,

This is with reference to the emails received from National Stock Exchange of India Limited and BSE Limited on April 16, 2025, on the captioned subject.

At the outset, we humbly submit that the Company believes in highest standard of corporate governance and makes all the necessary disclosures as and when mandated, within the statutory timelines prescribed.

We hereby inform that the United States District Court for the District of Delaware passed an order dated April 15, 2025 (received by the Company only in the morning hours of April 16, 2025) against the Company in the litigation matter pertaining to the validity of patent held by Astellas Pharma Inc., USA ("the **innovator**") for a sustained release formulation of 'mirabegron' marketed in the US by the innovator under the brand name Myrbetriq®.

We believe that today's material price movement in the equity shares of the Company is due to the announcement of above-mentioned order. We are evaluating the potential impact of the said order on the operations of the Company and the legal remedies available with the Company. The Company was about to provide necessary disclosure to the stock exchanges in terms of the prescribed time limit under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

No negotiations were taking place in this matter, as this was a patent litigation matter.

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878





Please find our above response in order.

Yours faithfully,  
For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary and Compliance Officer**  
**Membership No. FCS7063**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878

